Publication date: Sep 10, 2019
ROCKVILLE, Md. , Sept. 9, 2019 /PRNewswire/ –^A ExeGi Pharma has announced that researchers at Columbia University Irving Medical Center and the University of Pittsburgh will be examining the effects of their high potency probiotic, Visbiome, in patients with multiple sclerosis (MS).
The study will explore the effects of probiotics on the gut microbiota and immune systems of people living with MS. A previous study, published in Annals of Neurology in 2018, showed that administration of the same probiotic resulted in changes in the composition of gut microbiota in MS patients, along with an increase in anti-inflammatory biomarkers.
Rebecca Farber, MD, an assistant professor of neurology at Columbia University Vagelos College of Physicians and Surgeons, and one of the lead researchers on the study, says, “The gut microbiome plays an important role in modulating the immune system, which is dysregulated in individuals with MS. This study will enhance our understanding about whether probiotics may be able to advantageously reshape the immune system and prevent degeneration of the nervous system. “
|disease||MESH||irritable bowel syndrome|
|disease||DOID||irritable bowel syndrome|